Financial reports
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
26 Oct 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
10-Q
2022 Q1
Quarterly report
28 Apr 22
10-K
2021 FY
Annual report
24 Feb 22
10-Q
2021 Q3
Quarterly report
28 Oct 21
Current reports
8-K
Regulation FD Disclosure
27 Mar 24
8-K
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
22 Feb 24
8-K
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
18 Jan 24
8-K
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
9 Jan 24
8-K
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
8 Jan 24
8-K
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
4 Jan 24
8-K
Regulation FD Disclosure
28 Nov 23
8-K
Novocure Reports Third Quarter 2023 Financial Results
26 Oct 23
8-K
Regulation FD Disclosure
28 Aug 23
8-K
Novocure Reports Second Quarter 2023 Financial Results
27 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
22 Feb 24
S-8
Registration of securities for employees
23 Feb 23
S-8
Registration of securities for employees
24 Feb 22
S-8
Registration of securities for employees
25 Feb 21
S-8
Registration of securities for employees
3 Mar 20
S-8
Registration of securities for employees
30 Jul 19
S-8
Registration of securities for employees
2 May 18
S-8
Registration of securities for employees
3 May 17
S-8
Registration of securities for employees
1 Mar 16
424B3
Prospectus supplement
7 Oct 15
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
PRE 14A
Preliminary proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
Other
UPLOAD
Letter from SEC
14 Oct 20
UPLOAD
Letter from SEC
29 Sep 20
CT ORDER
Confidential treatment order
30 Oct 18
UPLOAD
Letter from SEC
19 Dec 17
CORRESP
Correspondence with SEC
15 Dec 17
UPLOAD
Letter from SEC
1 Dec 17
CT ORDER
Confidential treatment order
19 Oct 15
EFFECT
Notice of effectiveness
1 Oct 15
CORRESP
Correspondence with SEC
29 Sep 15
CORRESP
Correspondence with SEC
29 Sep 15
Ownership
4
WILHELMUS CM GROENHUYSEN
5 Mar 24
4
Frank X Leonard
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Ashley Cordova
29 Feb 24
4
Frank X Leonard
29 Feb 24